Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Christoffer Gebhardt: Can Anticoagulation Improve Outcomes in Melanoma Therapy?
Apr 9, 2026, 15:10

Christoffer Gebhardt: Can Anticoagulation Improve Outcomes in Melanoma Therapy?

Christoffer Gebhardt, Professor, Head of Skin Cancer Center and Vice Head of Department of Dermatology at The University Hospital Hamburg-Eppendorf, shared on LinkedIn:

”Antithrombotic therapies – particularly factor Xa inhibitors and anti-platelet agents – may limit melanoma metastasis and improve outcomes alongside established systemic treatments.

In patients receiving immune checkpoint inhibition (ICI), concomitant anticoagulation (AC) was associated with improved survival, while with targeted therapy (TT) concurrent AC enhanced both progression-free (PFS) and overall survival (OS).

Additionally, platelet inhibition with TT was linked to better OS after the first year.

These findings support the rationale for prospective clinical trials evaluating anticoagulation as a concomitant strategy in melanoma therapy.

Kudos to the first authors Julian Kött and Nina Matthes and all co-authors pushing translational research forward at the intersection of thrombosis and melanoma therapy!”

Title: Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence

Authors: Julian Kött, Nina Matthes, Alexander T Bauer, Noah Zimmermann, Tim Zell, Daniel J Smit, Stefan W Schneider, Christoffer Gebhardt

Read the Full Article on Journal for ImmunoTherapy of Cancer

Christoffer Gebhardt: Can Anticoagulation Improve Outcomes in Melanoma Therapy?

Stay updated on all scientific advances with Hemostasis Today.